IQVIA Holdings Inc. (IQV)
These Analysts Boost Their Forecasts On IQVIA After Better-Than-Expected Earnings
IQVIA Holdings Inc IQV posted better-than-expected second-quarter earnings on Monday.
Compared to Estimates, IQVIA (IQV) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for IQVIA (IQV) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
IQVIA Stock Pops After It Beats Q2 Earnings Estimates
IQVIA Holdings (IQV) beat second-quarter earnings expectations and raised its full-year outlook on Monday, sending shares higher.
IQVIA (IQV) Surpasses Earnings & Revenue Estimates in Q2
IQVIA's (IQV) second-quarter 2024 earnings and revenues increase year over year.
IQVIA 'Is A Solid Investment' With Strong Competitive Positioning, Analyst Says After Better Than Expected Q2 Earnings
IQVIA Holdings Inc IQV reported a second adjusted EPS of $2.64, up from $2.43, beating the consensus of $2.57.
IQVIA Holdings (IQV) Q2 Earnings and Revenues Surpass Estimates
IQVIA Holdings (IQV) came out with quarterly earnings of $2.64 per share, beating the Zacks Consensus Estimate of $2.58 per share. This compares to earnings of $2.43 per share a year ago.
IQVIA raises annual profit forecast on improving demand for analytics services
Contract research firm IQVIA Holdings raised its forecast for full-year profit on Monday, banking on strength in demand for its healthcare data and analytics services.
IQVIA (IQV) to Report Q2 Earnings: What's in the Offing?
IQVIA's (IQV) second-quarter 2024 revenues are likely to have gained from growth in the Technology and Analytics, and Research and Development segments.
Clinical Development Expertise Aids IQVIA (IQV), Costs High
IQVIA (IQV) benefits from its healthcare-specific global IT infrastructure and domain expertise to expand and penetrate different markets.
IQVIA (IQV) Announces Launch of Trial Technology Platform
IQVIA's (IQV) One Home for Sites allows pharmaceutical companies and their software vendors to streamline clinical application management.
IQVIA: Long-Term Compounder Throwing Off Free Cash Flow
There have been numerous positive updates to IQVIA Holdings' fundamental economics since January 2023. It produced strong Q1 2024 earnings, with growth observed in all segments. Increasing returns from margin growth and capital productivity are driving exceptional free cash flow production.
Here's Why You Should Hold on to IQVIA (IQV) Stock for Now
IQVIA (IQV) benefits from a powerful healthcare-specific global IT infrastructure and a robust real-world solutions ecosystem. However, high operating expenses are a headwind.
